96 related articles for article (PubMed ID: 16704682)
1. Hyperhomocysteinaemia and vascular access thrombosis among chronic hemodialysis patients in Taiwan: a retrospective study.
Chen TC; Wang IK; Lee CH; Chang HW; Chiou TT; Lee CT; Fang JT; Wu MS; Hsu KT; Yang CC; Wang PH; Chuang FR
Int J Clin Pract; 2006 Dec; 60(12):1596-9. PubMed ID: 16704682
[TBL] [Abstract][Full Text] [Related]
2. Anticardiolipin antibody and Taiwanese chronic haemodialysis patients with recurrent vascular access thrombosis.
Chuang FR; Chang HW; Lin CL; Wang IK; Chang HY; Wang PH; Yang CC; Chen TC; Wu CS; Lee CH
Int J Clin Pract; 2005 Jul; 59(7):785-90. PubMed ID: 15963205
[TBL] [Abstract][Full Text] [Related]
3. Anticardiolipin antibodies and vascular access thrombosis in Taiwanese haemodialysis patients with chronic hepatitis C: a retrospective study.
Lee CH; Wang IK; Chen TC; Chang HW; Yang CC; Chien YS; Wu CS; Chiou TT; Wu MS; Wang PH; Chuang FR
Int J Clin Pract; 2006 Dec; 60(12):1591-5. PubMed ID: 16704678
[TBL] [Abstract][Full Text] [Related]
4. Homocysteine and vascular access thrombosis in end-stage renal disease patients: a retrospective study.
Bowden RG; Wyatt FB; Wilson R
J Nephrol; 2002; 15(6):666-70. PubMed ID: 12495281
[TBL] [Abstract][Full Text] [Related]
5. The association between pulse pressure and vascular access thrombosis in chronic hemodialysis patients.
Chou CY; Liu JH; Kuo HL; Liu YL; Lin HH; Yang YF; Wang SM; Huang CC
Hypertens Res; 2009 Aug; 32(8):712-5. PubMed ID: 19590503
[TBL] [Abstract][Full Text] [Related]
6. IgM-anticardiolipin antibody and vascular access thrombosis in chronic hemodialysis patients.
Chuang FR; Chen TC; Yang CC; Cheng YF; Hsu KT; Lee CH; Lin CL; Wang IK; Chang HW; Wang PH
Ren Fail; 2005; 27(1):25-30. PubMed ID: 15717631
[TBL] [Abstract][Full Text] [Related]
7. Effect of route of EPO administration on hemodialysis arteriovenous vascular access failure: a randomized controlled trial.
Lee YK; Koo JR; Kim JK; Park II; Joo MH; Yoon JW; Noh JW; Vaziri ND
Am J Kidney Dis; 2009 May; 53(5):815-22. PubMed ID: 19324483
[TBL] [Abstract][Full Text] [Related]
8. Predictors of vascular access thrombosis among patients on the cadaveric renal transplantation waiting list.
Akman B; Afsar B; Ataç FB; Ibis A; Arat Z; Sezer S; Ozdemir FN; Haberal M
Transplant Proc; 2006 Mar; 38(2):413-5. PubMed ID: 16549134
[TBL] [Abstract][Full Text] [Related]
9. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
Lovcić V; Kes P; Zeljko R; Kusec V
Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
[TBL] [Abstract][Full Text] [Related]
10. C-reactive protein predicts vascular access thrombosis in hemodialysis patients.
Chou CY; Kuo HL; Yung YF; Liu YL; Huang CC
Blood Purif; 2006; 24(4):342-6. PubMed ID: 16601326
[TBL] [Abstract][Full Text] [Related]
11. Hyperhomocysteinemia and vascular access thrombosis in hemodialysis patients: a retrospective study.
Saifan C; El-Charabaty E; El-Sayegh S
Vasc Health Risk Manag; 2013; 9():361-4. PubMed ID: 23898227
[TBL] [Abstract][Full Text] [Related]
12. Relationship between hyperhomocysteinemia and atherosclerosis in chronic hemodialysis patients.
Taruangsri P; Ong-Ajyooth L; Ong-Ajyooth S; Chaiyasoot W; Leowattana W; Sritippayawan S; Vareesangthip K; Chanchairujira T; Vasuvattakul S; Shayakul C; Vanichakarn S
J Med Assoc Thai; 2005 Oct; 88(10):1373-81. PubMed ID: 16519382
[TBL] [Abstract][Full Text] [Related]
13. Vascular access outcomes and medication use: a USRDS study.
Yevzlin AS; Conley EL; Sanchez RJ; Young HN; Becker BN
Semin Dial; 2006; 19(6):535-9. PubMed ID: 17150056
[TBL] [Abstract][Full Text] [Related]
14. Hyperhomocysteinemia is a significant risk factor for silent cerebral infarction in patients with chronic renal failure undergoing hemodialysis.
Anan F; Takahashi N; Shimomura T; Imagawa M; Yufu K; Nawata T; Nakagawa M; Yonemochi H; Eshima N; Saikawa T; Yoshimatsu H
Metabolism; 2006 May; 55(5):656-61. PubMed ID: 16631443
[TBL] [Abstract][Full Text] [Related]
15. Hyperhomocysteinemia in inflammatory bowel disease patients without past intestinal resections: correlations with cobalamin, pyridoxine, folate concentrations, acute phase reactants, disease activity, and prior thromboembolic complications.
Erzin Y; Uzun H; Celik AF; Aydin S; Dirican A; Uzunismail H
J Clin Gastroenterol; 2008; 42(5):481-6. PubMed ID: 18344891
[TBL] [Abstract][Full Text] [Related]
16. Hyperhomocysteinaemia as a risk factor for deep-vein thrombosis.
Unlü Y; Keleş S; Becit N; Koçoğullari CU; Koçak H; Bakan E
Eur J Vasc Endovasc Surg; 2005 Sep; 30(3):315-8. PubMed ID: 15963742
[TBL] [Abstract][Full Text] [Related]
17. Thrombophilia and the risk for hemodialysis vascular access thrombosis.
Knoll GA; Wells PS; Young D; Perkins SL; Pilkey RM; Clinch JJ; Rodger MA
J Am Soc Nephrol; 2005 Apr; 16(4):1108-14. PubMed ID: 15728780
[TBL] [Abstract][Full Text] [Related]
18. Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients.
Manns BJ; Burgess ED; Parsons HG; Schaefer JP; Hyndman ME; Scott-Douglas NW
Kidney Int; 1999 Jan; 55(1):315-20. PubMed ID: 9893142
[TBL] [Abstract][Full Text] [Related]
19. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
Heinz J; Kropf S; Luley C; Dierkes J
Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
[TBL] [Abstract][Full Text] [Related]
20. Renal diagnosis of chronic hemodialysis patients with urinary tract transitional cell carcinoma in Taiwan.
Chang CH; Yang CM; Yang AH
Cancer; 2007 Apr; 109(8):1487-92. PubMed ID: 17330839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
